questionsmedicales.fr
Régions géographiques
Villes
Villes : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Villes : Questions médicales les plus fréquentes",
"headline": "Villes : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Villes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-31",
"dateModified": "2025-04-27",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Villes"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Régions géographiques",
"url": "https://questionsmedicales.fr/mesh/D005842",
"about": {
"@type": "MedicalCondition",
"name": "Régions géographiques",
"code": {
"@type": "MedicalCode",
"code": "D005842",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "Z01"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Baltimore",
"alternateName": "Baltimore",
"url": "https://questionsmedicales.fr/mesh/D015142",
"about": {
"@type": "MedicalCondition",
"name": "Baltimore",
"code": {
"@type": "MedicalCode",
"code": "D015142",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "Z01.433.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Pékin",
"alternateName": "Beijing",
"url": "https://questionsmedicales.fr/mesh/D000068476",
"about": {
"@type": "MedicalCondition",
"name": "Pékin",
"code": {
"@type": "MedicalCode",
"code": "D000068476",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "Z01.433.114"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Boston",
"alternateName": "Boston",
"url": "https://questionsmedicales.fr/mesh/D001900",
"about": {
"@type": "MedicalCondition",
"name": "Boston",
"code": {
"@type": "MedicalCode",
"code": "D001900",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "Z01.433.210"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Chicago",
"alternateName": "Chicago",
"url": "https://questionsmedicales.fr/mesh/D002641",
"about": {
"@type": "MedicalCondition",
"name": "Chicago",
"code": {
"@type": "MedicalCode",
"code": "D002641",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "Z01.433.305"
}
}
},
{
"@type": "MedicalWebPage",
"name": "District de Columbia",
"alternateName": "District of Columbia",
"url": "https://questionsmedicales.fr/mesh/D004219",
"about": {
"@type": "MedicalCondition",
"name": "District de Columbia",
"code": {
"@type": "MedicalCode",
"code": "D004219",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "Z01.433.429"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Los Angeles",
"alternateName": "Los Angeles",
"url": "https://questionsmedicales.fr/mesh/D015141",
"about": {
"@type": "MedicalCondition",
"name": "Los Angeles",
"code": {
"@type": "MedicalCode",
"code": "D015141",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "Z01.433.565"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Nouvelle-Orléans",
"alternateName": "New Orleans",
"url": "https://questionsmedicales.fr/mesh/D055820",
"about": {
"@type": "MedicalCondition",
"name": "Nouvelle-Orléans",
"code": {
"@type": "MedicalCode",
"code": "D055820",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "Z01.433.697"
}
}
},
{
"@type": "MedicalWebPage",
"name": "New York (ville)",
"alternateName": "New York City",
"url": "https://questionsmedicales.fr/mesh/D009519",
"about": {
"@type": "MedicalCondition",
"name": "New York (ville)",
"code": {
"@type": "MedicalCode",
"code": "D009519",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "Z01.433.741"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Philadelphie",
"alternateName": "Philadelphia",
"url": "https://questionsmedicales.fr/mesh/D015143",
"about": {
"@type": "MedicalCondition",
"name": "Philadelphie",
"code": {
"@type": "MedicalCode",
"code": "D015143",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "Z01.433.820"
}
}
},
{
"@type": "MedicalWebPage",
"name": "San Francisco",
"alternateName": "San Francisco",
"url": "https://questionsmedicales.fr/mesh/D012495",
"about": {
"@type": "MedicalCondition",
"name": "San Francisco",
"code": {
"@type": "MedicalCode",
"code": "D012495",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "Z01.433.875"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Séoul",
"alternateName": "Seoul",
"url": "https://questionsmedicales.fr/mesh/D066106",
"about": {
"@type": "MedicalCondition",
"name": "Séoul",
"code": {
"@type": "MedicalCode",
"code": "D066106",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "Z01.433.887"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Tokyo",
"alternateName": "Tokyo",
"url": "https://questionsmedicales.fr/mesh/D014041",
"about": {
"@type": "MedicalCondition",
"name": "Tokyo",
"code": {
"@type": "MedicalCode",
"code": "D014041",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "Z01.433.900"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Villes",
"alternateName": "Cities",
"code": {
"@type": "MedicalCode",
"code": "D002947",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Divya Seth",
"url": "https://questionsmedicales.fr/author/Divya%20Seth",
"affiliation": {
"@type": "Organization",
"name": "Division of Allergy/Immunology, Department of Pediatrics, Children's Hospital of Michigan, Wayne State University School of Medicine, 3950 Beaubien, 4th Floor, Pediatric Specialty Building, Detroit, MI 48201, USA. Electronic address: dseth@dmc.org."
}
},
{
"@type": "Person",
"name": "Shweta Saini",
"url": "https://questionsmedicales.fr/author/Shweta%20Saini",
"affiliation": {
"@type": "Organization",
"name": "Division of Hospital Medicine, Department of Pediatrics, Children's Hospital of Michigan, Wayne State University School of Medicine, Detroit, MI, USA."
}
},
{
"@type": "Person",
"name": "Pavadee Poowuttikul",
"url": "https://questionsmedicales.fr/author/Pavadee%20Poowuttikul",
"affiliation": {
"@type": "Organization",
"name": "Division of Allergy/Immunology, Department of Pediatrics, Children's Hospital of Michigan, Wayne State University School of Medicine, Detroit, MI, USA."
}
},
{
"@type": "Person",
"name": "Marc Barthelemy",
"url": "https://questionsmedicales.fr/author/Marc%20Barthelemy",
"affiliation": {
"@type": "Organization",
"name": "Université Paris-Saclay, CEA, CNRS, Institut de Physique Théorique, 91191 Gif-sur-Yvette, France."
}
},
{
"@type": "Person",
"name": "Sasha Khomenko",
"url": "https://questionsmedicales.fr/author/Sasha%20Khomenko",
"affiliation": {
"@type": "Organization",
"name": "Institute for Global Health, Barcelona, Spain; Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Multidimensional biomarkers for multiple system atrophy: an update and future directions.",
"datePublished": "2023-07-28",
"url": "https://questionsmedicales.fr/article/37501056",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s40035-023-00370-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Quantitative assessment of oculomotor function by videonystagmography in multiple system atrophy.",
"datePublished": "2022-06-21",
"url": "https://questionsmedicales.fr/article/35809545",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clinph.2022.05.019"
}
},
{
"@type": "ScholarlyArticle",
"name": "Mild cognitive impairment in multiple system atrophy: a brain network disorder.",
"datePublished": "2023-08-15",
"url": "https://questionsmedicales.fr/article/37581647",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00702-023-02682-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Determinants of cognitive impairment in multiple system atrophy: Clinical and genetic study.",
"datePublished": "2022-12-12",
"url": "https://questionsmedicales.fr/article/36508411",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0277798"
}
},
{
"@type": "ScholarlyArticle",
"name": "Multiple system atrophy: α-Synuclein strains at the neuron-oligodendrocyte crossroad.",
"datePublished": "2022-11-26",
"url": "https://questionsmedicales.fr/article/36435784",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13024-022-00579-z"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Régions géographiques",
"item": "https://questionsmedicales.fr/mesh/D005842"
},
{
"@type": "ListItem",
"position": 3,
"name": "Villes",
"item": "https://questionsmedicales.fr/mesh/D002947"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Villes - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Villes",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-11",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Villes",
"description": "Comment évaluer l'impact de la pollution urbaine sur la santé ?\nQuels tests sont utilisés pour diagnostiquer les maladies liées aux villes ?\nComment identifier les zones à risque sanitaire en ville ?\nQuels indicateurs de santé sont pertinents en milieu urbain ?\nComment évaluer l'accès aux soins en ville ?",
"url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Multiple+System+Atrophy&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Villes",
"description": "Quels symptômes sont liés à la pollution de l'air ?\nComment la vie urbaine affecte-t-elle la santé mentale ?\nQuels symptômes sont associés à la chaleur urbaine ?\nQuels signes indiquent une mauvaise qualité de l'eau en ville ?\nQuels symptômes sont liés à l'isolement social en ville ?",
"url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Multiple+System+Atrophy&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Villes",
"description": "Comment prévenir les maladies liées à la pollution en ville ?\nQuelles mesures peuvent réduire le stress urbain ?\nComment améliorer la qualité de l'eau en milieu urbain ?\nQuelles stratégies aident à prévenir les coups de chaleur ?\nComment favoriser la santé mentale en milieu urbain ?",
"url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Multiple+System+Atrophy&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Villes",
"description": "Quels traitements sont efficaces contre les maladies respiratoires urbaines ?\nComment traiter les effets de la chaleur extrême en ville ?\nQuels traitements sont disponibles pour le stress urbain ?\nComment traiter les maladies liées à l'eau contaminée ?\nQuels traitements sont recommandés pour l'anxiété urbaine ?",
"url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Multiple+System+Atrophy&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Villes",
"description": "Quelles complications peuvent survenir à cause de la pollution ?\nQuels risques de santé sont liés à l'isolement social ?\nQuelles complications peuvent résulter de la chaleur extrême ?\nComment la qualité de l'eau affecte-t-elle la santé ?\nQuelles complications sont liées à la vie urbaine ?",
"url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Multiple+System+Atrophy&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Villes",
"description": "Quels facteurs de risque sont associés à la pollution urbaine ?\nComment le stress urbain influence-t-il la santé ?\nQuels sont les risques liés à la chaleur en milieu urbain ?\nQuels facteurs augmentent le risque de maladies infectieuses en ville ?\nQuels comportements augmentent le risque de problèmes de santé en ville ?",
"url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Multiple+System+Atrophy&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment évaluer l'impact de la pollution urbaine sur la santé ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'impact se mesure par des études épidémiologiques et des indicateurs de santé."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour diagnostiquer les maladies liées aux villes ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de laboratoire, des examens cliniques et des enquêtes de santé sont utilisés."
}
},
{
"@type": "Question",
"name": "Comment identifier les zones à risque sanitaire en ville ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'analyse géospatiale et les données de santé publique aident à identifier ces zones."
}
},
{
"@type": "Question",
"name": "Quels indicateurs de santé sont pertinents en milieu urbain ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les taux de maladies respiratoires, cardiovasculaires et d'obésité sont des indicateurs clés."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'accès aux soins en ville ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'accès se mesure par la distance aux établissements de santé et la disponibilité des services."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à la pollution de l'air ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent toux, essoufflement, irritation des yeux et fatigue."
}
},
{
"@type": "Question",
"name": "Comment la vie urbaine affecte-t-elle la santé mentale ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress, l'anxiété et la dépression sont souvent exacerbés par la vie urbaine."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés à la chaleur urbaine ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent déshydratation, épuisement et coups de chaleur."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une mauvaise qualité de l'eau en ville ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes incluent des maladies gastro-intestinales et des éruptions cutanées."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à l'isolement social en ville ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'isolement peut entraîner des symptômes de dépression et d'anxiété."
}
},
{
"@type": "Question",
"name": "Comment prévenir les maladies liées à la pollution en ville ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des politiques de réduction de la pollution et des campagnes de sensibilisation sont essentielles."
}
},
{
"@type": "Question",
"name": "Quelles mesures peuvent réduire le stress urbain ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Promouvoir des espaces verts et des activités communautaires aide à réduire le stress."
}
},
{
"@type": "Question",
"name": "Comment améliorer la qualité de l'eau en milieu urbain ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des systèmes de filtration et des contrôles réguliers de la qualité de l'eau sont nécessaires."
}
},
{
"@type": "Question",
"name": "Quelles stratégies aident à prévenir les coups de chaleur ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éduquer sur l'hydratation et l'ombre, et créer des refuges frais sont des stratégies clés."
}
},
{
"@type": "Question",
"name": "Comment favoriser la santé mentale en milieu urbain ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Encourager le soutien social et l'accès à des services de santé mentale est crucial."
}
},
{
"@type": "Question",
"name": "Quels traitements sont efficaces contre les maladies respiratoires urbaines ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les bronchodilatateurs, corticostéroïdes et thérapies respiratoires sont courants."
}
},
{
"@type": "Question",
"name": "Comment traiter les effets de la chaleur extrême en ville ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut l'hydratation, le repos et, si nécessaire, des soins médicaux."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour le stress urbain ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie cognitivo-comportementale et les médicaments peuvent aider à gérer le stress."
}
},
{
"@type": "Question",
"name": "Comment traiter les maladies liées à l'eau contaminée ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut l'hydratation, des antibiotiques et des soins symptomatiques."
}
},
{
"@type": "Question",
"name": "Quels traitements sont recommandés pour l'anxiété urbaine ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les thérapies psychologiques et les médicaments anxiolytiques sont souvent prescrits."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir à cause de la pollution ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des maladies respiratoires chroniques et des cancers."
}
},
{
"@type": "Question",
"name": "Quels risques de santé sont liés à l'isolement social ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'isolement peut entraîner des maladies cardiovasculaires et des troubles mentaux."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent résulter de la chaleur extrême ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des coups de chaleur, des déshydratations sévères et des décès."
}
},
{
"@type": "Question",
"name": "Comment la qualité de l'eau affecte-t-elle la santé ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une mauvaise qualité de l'eau peut entraîner des infections et des maladies gastro-intestinales."
}
},
{
"@type": "Question",
"name": "Quelles complications sont liées à la vie urbaine ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'anxiété, la dépression et des maladies chroniques."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés à la pollution urbaine ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'industrialisation, le trafic routier et l'urbanisation rapide."
}
},
{
"@type": "Question",
"name": "Comment le stress urbain influence-t-il la santé ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress peut aggraver des conditions comme l'hypertension et l'anxiété."
}
},
{
"@type": "Question",
"name": "Quels sont les risques liés à la chaleur en milieu urbain ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées et celles avec des maladies chroniques sont particulièrement à risque."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de maladies infectieuses en ville ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "La densité de population et l'accès limité à l'eau potable augmentent les risques."
}
},
{
"@type": "Question",
"name": "Quels comportements augmentent le risque de problèmes de santé en ville ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le tabagisme, la sédentarité et une alimentation déséquilibrée sont des comportements à risque."
}
}
]
}
]
}
Multiple system atrophy (MSA) is a fatal progressive neurodegenerative disease. Biomarkers are urgently required for MSA to improve the diagnostic and prognostic accuracy in clinic and facilitate the ...
To quantitatively assess oculomotor impairments in multiple system atrophy (MSA) and to explore their correlation with clinical characteristics....
We recruited 45 patients with MSA, including 21 with dominant ataxia (MSA-C), 24 with dominant parkinsonism (MSA-P), and 40 age-matched healthy controls. Detailed oculomotor performance in the horizon...
We found that the proportion of abnormal eye movements in patients with MSA was 93.3% (37.7%, 51.1%, 73.3%, 71.1%, and 37.8% on fixation and gaze-holding, without fixation, saccade, smooth pursuit, an...
An extremely high incidence of oculomotor impairments could be observed using VNG in both the MSA-C and MSA-P subtypes, although there were some differences between them....
A comprehensive oculomotor examination could serve as a valuable tool in the diagnostic workup of patients with MSA....
Cognitive impairment (CI), previously considered as a non-supporting feature of multiple system atrophy (MSA), according to the second consensus criteria, is not uncommon in this neurodegenerative dis...
Classically, cognitive impairment (CI) was not considered as a paramount feature of multiple system atrophy(MSA) in both parkinsonian(MSA-P) and cerebellar(MSA-C) motor-subtypes. Yet, growing evidence...
In a retrospective cross-sectional study, clinically-diagnosed MSA patients were included. All subjects underwent clinical and neuropsychological assessments to characterize their cognitive profile. T...
We included 71 MSA patients. Female gender(sex-ratio = 0.65) and MSA-P subtype(73%) were predominant. Mean age of disease onset was 59.1years. CI was found in 85.7% of patients(dementia in 12.7% and M...
In this study, the main determinants of CI in Tunisian MSA patients were MSA-P motor-subtype, mainly of PIGD-phenotype, disease duration and APOEε4 carrying status, defining a more altered cognitive p...
The aberrant accumulation of α-Synuclein within oligodendrocytes is an enigmatic, pathological feature specific to Multiple system atrophy (MSA). Since the characterization of the disease in 1969, dec...
Orthostatic hypotension (OH) is one of the most important autonomic features of multiple system atrophy (MSA). This study was established to confirm the correlation between lipid levels and OH in MSA....
A total of 580 patients with probable or possible MSA from neurological wards in six hospitals in Tianjin, Beijing, Hebei Province, and Henan Province, China, were included in this study. The tilt tes...
Serum levels of total cholesterol, LDL-C, and triglyceride in MSA-OH patients were significantly lower than those in MSA without OH. The risks of OH were significantly higher in the lowest quartiles o...
Low levels of TC, LDL-C, and triglyceride increased the risk of OH in MSA. A low level of triglyceride predicted severe OH in MSA....
Differentiation cerebellar multiple systemic atrophy (MSA-C) from spinocerebellar ataxia (SCA) is important. The "hot cross bun" sign (HCBS) at pons and magnetic resonance spectroscopy (MRS) are helpf...
We evaluated the value of electrophysiological indicators by external anal sphincter electromyography (EAS-EMG), sympathetic skin response (SSR), R-R interval variation (RRIV), and Bulbocavernosus Ref...
A total of 41 patients with MSA and 32 patients with PD were enrolled. The electrophysiological changes of autonomic dysfunction were assessed with BCR, EAS-EMG, SSR, and RRIV, and the abnormal rate o...
The incidence rate of autonomic dysfunction in MSA group was significantly higher than that in PD group (p < 0.05). The abnormal rates of BCR and EAS-EMG indicators in MSA group were higher than those...
Combined analysis of BCR and EAS-EMG has high sensitivity and specificity for differential diagnosis of MSA and PD....
Multiple system atrophy (MSA) is a progressive neurodegenerative disorder caused by the abnormal accumulation of α-synuclein in the nervous system. Clinical features include autonomic and motor dysfun...
We studied 31 patients with MSA and 54 patients with PD diagnosed according to current clinical consensus criteria. We also included 24 matched controls. All participants underwent neurologic examinat...
Patients with PD had reduced nerve fiber densities compared with patients with MSA (...
α-synuclein is present in the peripheral autonomic nerves of patients with MSA and when combined with synuclein distribution accurately distinguishes MSA from PD....
This study provides Class II evidence that measurement of phosphorylated α-synuclein in skin biopsies can differentiate patients with MSA from those with PD....
Multiple System Atrophy (MSA) is a rare neurodegenerative disease with pronounced autonomic failure (AF). Severe cardiovascular AF is associated with poor prognosis. Since sweating dysfunction is less...
138 MSA patients of the French Reference center for MSA with an annual follow-up including the Unified MSA Rating Scale (UMSARS), COMPASS (autonomic symptoms) and measurements of foot and hand ESC (Su...
Hands and feet ESCs were abnormal in 81/138 (59%) and 93/138 (67%) cases, respectively. Abnormal ESCs were significantly correlated to disease severity and several features of AF. ESCs worsening over ...
Sweating dysfunction assessed by ESC is frequent in MSA and is significantly related to disease severity and AF. The gradual decrease in ESC with disease duration could be useful as a quantitative mar...